No Data
No Data
NKGen Biotech's Strategic Stock Purchase Agreement
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations
CEO Makes Bold Move With Massive NKGen Biotech Stock Purchase
NKGen Biotech Delays Annual Report Filing
NKGen Biotech To Present On Potential Of Troculeucel For The Treatment Of Neurodegenerative Diseases At The 13th Annual Alzheimer's & Parkinson's Drug Development Summit March 18–20, 2025
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit